Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Study finds...

    Study finds combination antibiotic Avycaz, safe and effective for complicated UTIs in children

    Written by Medha Baranwal Baranwal Published On 2019-08-08T20:20:29+05:30  |  Updated On 19 Aug 2021 5:41 PM IST

    Delhi: The combination antibiotic Avycaz (ceftazidime-avibactam) is safe and well-tolerated in children with complicated urinary tract infections (cUTIs), suggests findings from a phase 2 study published in The Pediatric Infectious Disease Journal.


    The safety profile of the drug was found to be consistent with that of adults with cUTI and appeared effective in children with cUTI due to Gram-negative pathogens.


    Avycaz (ceftazidime-avibactam, Forest Pharmaceuticals) was approved in 2015 for the treatment of adults with cUTIs, including kidney infections. It is also indicated for complicated intra-abdominal infections (cIAIs) and nosocomial pneumonia. However, the drug is still not been evaluated in children with cUTI.


    John S. Bradley, director of the division of infectious diseases at Rady Children's Hospital-San Diego, and colleagues conducted this single-blind, multicenter, active-controlled, phase 2 study to evaluate the safety and efficacy of Avycaz in children.


    In the study, children aged 3 months to 18 years with cUTIs were randomized to receive IV ceftazidime-avibactam (n = 67) or cefepime (n = 28) for at least 72 hours. The children then had the option of switching to an oral regimen, which resulted in a treatment duration that ranged between 7 and 14 days.


    Key findings include:

    • The predominant baseline Gram-negative uropathogen was Escherichia coli (92.2%).

    • Adverse events (AEs) occurred in 53.7% and 53.6% patients in the ceftazidime-avibactam and cefepime groups, respectively.

    • Serious AEs occurred in 11.9% (ceftazidime-avibactam) and 7.1% (cefepime) patients.

    • One serious AE (ceftazidime-avibactam group) was considered drug-related.

    • In the microbiological intent-to-treat analysis set, favourable clinical response rates >95% were observed for both groups at end-of-IV and remained 88.9% (ceftazidime-avibactam) and 82.6% (cefepime) at test-of-cure.

    • Favorable per-patient microbiological response at test-of-cure was 79.6% (ceftazidime-avibactam) and 60.9% (cefepime).


    "The most common bacterial pathogen for complicated UTI is Escherichia coli, and about 50% of community isolates are resistant to ampicillin, which was commonly used as first-line therapy 30 years ago, with ceftriaxone subsequently being the most active antibiotic until the emergence of extended-spectrum beta-lactamases," Bradley explained.


    "Now, we are seeing the slow emergence of E. coli and Klebsiella that are resistant to meropenem and that are often also resistant to ciprofloxacin and gentamicin. We need therapy for these emerging strains for both hospitalized children who may develop nosocomial infections and for the inevitable spread of these multidrug-resistant pathogens to the community."

    cefepimeCeftazidimeCiprofloxacincombination drugdrug safetyE colieffectiveEscherichia coligentamicinJohn S. BradleyMedical newsPediatric Infectious Disease JournalPhase 2 studyrecent medical newssafeUrinary Tract InfectionsUTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok